Department of Medicine, Services of Cytometry and Hematology and Cancer Research Center (CIC, IBMCC USAL-CSIC), University of Salamanca and University Hospital of Salamanca, Salamanca, Spain.
Cytometry B Clin Cytom. 2010 Jul;78(4):239-52. doi: 10.1002/cyto.b.20512.
In recent years, multiparameter flow cytometry (MFC) immunophenotyping has become mandatory in the clinical management of hematological malignancies, both for diagnostic and monitoring purposes. Multiple myeloma (MM) and other clonal plasma cell-related (PC) disorders should be no exception to this paradigm, but incorporation of immunophenotypic studies in the management of patients with PC disorders is still far from being routinely established in many diagnostic flow cytometry laboratories. For clonal PC disorders, MFC is of clear and established clinical relevance in: (1) the differential diagnosis between MM and other PC-related disorders; (2) the identification of high-risk MGUS and smoldering MM; (3) minimal residual disease investigation after therapy; additionally it may also be useful for (4) the definition of prognosis-associated antigenic profiles; and (5) the identification of new therapeutic targets. In this article, we review the clinical value of MFC in the study of PC disorders, with specific emphasis in those areas where consensus exists on the need to incorporate MFC into routine evaluation of MM and other clonal PC-related disorders.
近年来，多参数流式细胞术（MFC）免疫表型分析已成为血液恶性肿瘤临床管理的强制性要求，无论是诊断还是监测目的。多发性骨髓瘤（MM）和其他克隆性浆细胞相关（PC）疾病也不例外，但在许多诊断流式细胞实验室中，将免疫表型研究纳入 PC 疾病的管理仍远未得到常规应用。对于克隆性 PC 疾病，MFC 在以下方面具有明确和已确立的临床相关性：（1）MM 与其他 PC 相关疾病的鉴别诊断；（2）高危 MGUS 和冒烟型 MM 的识别；（3）治疗后微小残留病的研究；此外，它还可能对（4）定义与预后相关的抗原谱；和（5）确定新的治疗靶点。本文回顾了 MFC 在 PC 疾病研究中的临床价值，特别强调了在那些需要将 MFC 纳入 MM 和其他克隆性 PC 相关疾病常规评估的领域中存在共识的方面。
